Category: Incretins

Hello AstraZeneca: #Onglyza Database

Ramirez, Jorge H (2015): ClinicalTrials.gov – 101 studies found for: saxagliptin (search date: April 12, 2015). figshare. http://dx.doi.org/10.6084/m9.figshare.1375296 HT PharmaGossip: “Pulls”! Really? FDA Pulls Diabetes Drug Onglyza Citing Increased Risk Of Death | Multisource Video News Analysis http://t.co/kbeRKktVE6? — pharmagossip (@pharmagossip) abril 11, 2015 #astrazeneca #Onglyza . What the #FDA is saying: http://t.co/iatyEsglr3 — pharmagossip…

Incretin mimetics: liraglutide (Victoza) unpublished studies (ClinicalTrials.gov, EudraCT, and UMIN) → 69%

Originally posted on Chaos Theory and Pharmacology:
  Background: “Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage” – Re: let’s start this discussion again Unpublished & published liraglutide studies in humans – Completed before Jan 1, 2011 – – Unpublished (n=37): 68.5% – Published (n=17): 31.5% → 3.1 papers per published study record. 90% of the studies (35…

“Incorrect statements by Novo Nordisk” ―Peter C. Gøtzsche| cc @FedeMedicaC @ENDOCRINO_COL

Moses Alan. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage. BMJ 2013; 347:f4386. 10.1136/bmj.f4386  Re: Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage. http://www.bmj.com/content/347/bmj.f4386/rr/657934 Peter C Gøtzsche Professor Nordic Cochrane Centre Copenhagen 16 August 2013 “Incorrect statements by Novo Nordisk Alan Moses, global chief medical officer at Novo Nordisk, states that…

About the safety and effectiveness of incretins (gliptins) in type 2 diabetic patients

  1. Towards better patient care: drugs to avoid in 2014 ―Prescrire International English – Medicamentos peligrosos (By Prescrire): analysis by Plataforma NoGracias.       – Boletin Med-Informatica, Federación Médica Colombiana. PRESCRIRE Internacional Incluye Sitagliptina, Saxagliptina y Linagliptina en Lista Negativa de Medicamentos Inservibles (2014). 2. BMJ Open Data Campaign: Incretin Mimetics “Incretin therapies—glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4…

Incretin mimetics: liraglutide (Victoza) unpublished studies (ClinicalTrials.gov, EudraCT, and UMIN) → 69%

  Background: “Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage” – Re: let’s start this discussion again Unpublished & published liraglutide studies in humans – Completed before Jan 1, 2011 – – Unpublished (n=37): 68.5% – Published (n=17): 31.5% → 3.1 papers per published study record. 90% of the studies (35 / 39) were retrospectively registered Median (Interquartile range: Q1…